TNF and ankylosing spondylitis disease activity score: In this study, C6M was reduced by TNF-inhibitory therapy, associated with clinically important and major improvement in ASDAS disease activity at weeks 22 and 46, and it moderately correlated with the total SPARCC MRI Spine and Sacroiliac Joint Inflammation score, and differentiated responders from non-responders after 22 weeks.